Halozyme to Report Second Quarter 2026 Financial and Operating Results
Go back to Halozyme to Report Second Quarter 2026 Financial and Operating Results| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 106.27 -1.35 (1.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $107.62 | 52 Week High | $18.39 | |||
| Open | $106.41 | 52 Week Low | $6.96 | |||
| Day High | $107.44 | P/E | N/A | |||
| Day Low | $105.20 | EPS | $-0.58 | |||
| Volume | 761,921 | |||||
